Abstract B07: Design and preliminary outcomes of a study to reduce cancer-associated reactive metabolite levels in breast cancer survivors – The RCAM Study

Abstract

Abstract Breast cancer (BCa) is the 2nd leading cause of cancer death in women in the US. African American (AA) women have higher BCa mortality rates and higher obesity rates compared to other women. It is well known that exercise and a healthier diet can improve prognosis among BCa survivors but little is known about their positive effects on common biological pathways involved in BCa recurrence. The RCAM Study is a 1-year study designed to identify bio-behavioral pathways that may impact BCa recurrence. The study evaluates the effect of the intervention on a novel biomarker associated with cancer recurrence advanced glycation end products (AGEs). The intervention, adapted from the highly successful Diabetes Prevention Program (DPP), consists of a 12-week physical activity and dietary counseling program. The supervised physical activity component is conducted twice a week at a local health system's cardiopulmonary rehabilitation center; the individualized dietary counseling component is conducted weekly at the health system's weight management center. The study participants consist of overweight or obese women who received surgery for invasive BCa and who are within 36 months of diagnosis. In addition, adjuvant therapy must have been received at least four weeks prior to study enrollment. To date, 10 participants have completed the 12-week intervention and will be followed for 1 year. Preliminary ELISA data from blood samples collected pre- and post-12 week intervention show significant post-intervention reductions in inflammatory biomarker levels. Commensurate decreases in body mass, resting heart rate, and blood pressure were also seen. The average pre-/post-intervention decrease in AGE levels was not as dramatic for the AA participants, most of whom were morbidly obese at enrollment, as for the European American (EA) women, most of whom were overweight at enrollment. These data demonstrate the high potential of the RCAM intervention in improving prognosis among BCa survivors and show the need to tailor the intervention to meet the specific needs of AA women. Citation Format: Marvella E. Ford, David P. Turner, Mathew J. Gregoski, Lindsay L. Peterson, Kendrea D. Knight, Ebony J. Hilton, Gayenell Magwood. Design and preliminary outcomes of a study to reduce cancer-associated reactive metabolite levels in breast cancer survivors – The RCAM Study. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr B07.